{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:07:15Z","timestamp":1792667235594,"version":"4.5.0"},"reference-count":241,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010018","name":"Doctoral Start-up Foundation of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunogenic cell death (ICD) is a regulated cell death (RCD) pathway. In response to physical and chemical signals, tumor cells activate specific signaling pathways that stimulate stress responses in the endoplasmic reticulum (ER) and expose damage-associated molecular patterns (DAMPs), which promote antitumor immune responses. As a result, the tumor microenvironment is altered, and many tumor cells are killed. The ICD response in tumor cells requires inducers. These inducers can be from different sources and contribute to the development of the ICD either indirectly or directly. The combination of ICD inducers with other tumor treatments further enhances the immune response in tumor cells, and more tumor cells are killed; however, it also produces side effects of varying severity. New induction methods based on nanotechnology improve the antitumor ability and significantly reduces side effects because they can target tumor cells precisely. In this review, we introduce the characteristics and mechanisms of ICD responses in tumor cells and the DAMPs associated with ICD responses, summarize the current methods of inducing ICD response in tumor cells in five distinct categories: chemical sources, physical sources, pathogenic sources, combination therapies, and innovative therapies. At the same time, we introduce the limitations of current ICD inducers and make a summary of the use of ICD responses in clinical trials. Finally, we provide an outlook on the future of ICD inducer development and provide some constructive suggestions.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1017400","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T04:59:50Z","timestamp":1668661190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Research progress in inducing immunogenic cell death of tumor cells"],"prefix":"10.3389","volume":"13","author":[{"given":"Deqian","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12025","article-title":"Cancer burden of major cancers in China: A need for sustainable actions","volume":"40","author":"Cao","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B2","unstructured":""},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the united states and united kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity\u2013focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2363","article-title":"Advances in systemic therapy for non-small cell lung cancer","volume":"375","author":"Miller","year":"2021","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0164-5","article-title":"The molecular machinery of regulated cell death","volume":"29","author":"Tang","year":"2019","journal-title":"Cell Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/03009858211005537","article-title":"Mechanisms of regulated cell death: Current perspectives","volume":"58","author":"Santagostino","year":"2021","journal-title":"Vet Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122709","article-title":"Regulated necrotic cell death in alternative tumor therapeutic strategies","volume":"9","author":"Woo","year":"2020","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23183","article-title":"Immunogenic cell death in colon cancer prevention and therapy","volume":"59","author":"Ruan","year":"2020","journal-title":"Mol Carcinog"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2019","journal-title":"Med (Kaunas)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.01.005","article-title":"Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation","volume":"32","author":"Krysko","year":"2011","journal-title":"Trends Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2012.02.009","article-title":"Calreticulin signaling in health and disease","volume":"44","author":"Wang","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-012-9600-2","article-title":"Calreticulin and cancer","volume":"19","author":"Zamanian","year":"2013","journal-title":"Pathol Oncol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ncomms1524","article-title":"CD91-dependent programming of T-helper cell responses following heat shock protein immunization","volume":"2","author":"Pawaria","year":"2011","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-019-01532-0","article-title":"Calreticulin in phagocytosis and cancer: opposite roles in immune response outcomes","volume":"24","author":"Schcolnik-Cabrera","year":"2019","journal-title":"Apoptosis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/107999004323142187","article-title":"Extracellular HMGB1 as a proinflammatory cytokine","volume":"24","author":"Chen","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","article-title":"The mechanism of HMGB1 secretion and release","volume":"54","author":"Chen","year":"2022","journal-title":"Exp Mol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-008-9093-5","article-title":"Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1)","volume":"11","author":"van Beijnum","year":"2008","journal-title":"Angiogenesis"},{"key":"B32","article-title":"Dealing with death: HMGB1 as a novel target for cancer therapy","volume":"4","author":"Lotze","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-06130-x","article-title":"Expatiating the molecular approaches of HMGB1 in diabetes mellitus: Highlighting signalling pathways via RAGE and TLRs","volume":"48","author":"Behl","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315151","article-title":"Internalization of HMGB1 (High mobility group box 1) promotes angiogenesis in endothelial cells","volume":"40","author":"Lan","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112496","article-title":"Extracellular ATP: A feasible target for cancer therapy","volume":"9","author":"Vultaggio-Poma","year":"2020","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1138-4","article-title":"Autophagy and autophagy-related proteins in cancer","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 purinergic signalling in the tumour microenvironment","volume":"18","author":"Di Virgilio","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108130","article-title":"ATP and cancer immunosurveillance","volume":"40","author":"Kepp","year":"2021","journal-title":"EMBO J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.32607\/actanaturae.11523","article-title":"Immunogenic cell death in cancer therapy","volume":"14","author":"Troitskaya","year":"2022","journal-title":"Acta Naturae"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.11.009","article-title":"Heat shock proteins and cancer","volume":"38","author":"Wu","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010060","article-title":"Heat shock proteins: Agents of cancer development and therapeutic targets in anti-cancer therapy","volume":"9","author":"Yun","year":"2019","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.056","article-title":"Targeting Hsp70: A possible therapy for cancer","volume":"374","author":"Kumar","year":"2016","journal-title":"Cancer Lett"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092560","article-title":"The HSP90 family: Structure, regulation, function, and implications in health and disease","volume":"19","author":"Hoter","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4103\/2319-4170.113230","article-title":"Structure, function and regulation of the hsp90 machinery","volume":"36","author":"Li","year":"2013","journal-title":"BioMed J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040959","article-title":"Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy","volume":"20","author":"Rapoport","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-065X.2008.00698.x","article-title":"Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha\/beta, IFN-gamma, and IFN-lambda in host defense","volume":"226","author":"Zhang","year":"2008","journal-title":"Immunol Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxt050","article-title":"Confounding roles for type I interferons during bacterial and viral pathogenesis","volume":"25","author":"Carrero","year":"2013","journal-title":"Int Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903510880","article-title":"Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity","volume":"43","author":"Rizza","year":"2010","journal-title":"Autoimmunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"biomark Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00496","article-title":"Type I interferon-independent dendritic cell priming and antitumor T cell activation induced by a mycoplasma fermentans lipopeptide","volume":"9","author":"Takeda","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0403","article-title":"Sustained type I interferon reinforces NK cell-mediated cancer immunosurveillance during chronic virus infection","volume":"7","author":"Jh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01383","article-title":"Toll-like receptor ligands and interferon-\u03b3 synergize for induction of antitumor M1 macrophages","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006985","article-title":"Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment","volume":"14","author":"Gangaplara","year":"2018","journal-title":"PloS Pathog"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.06.010","article-title":"ER stress-induced inflammation: does it aid or impede disease progression","volume":"18","author":"Garg","year":"2012","journal-title":"Trends Mol Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00544-2","article-title":"Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression","volume":"43","author":"Li","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"Terenzi","year":"2016","journal-title":"J Inorg Biochem"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105265","article-title":"MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance","volume":"163","author":"Xu","year":"2021","journal-title":"Pharmacol Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41419-021-03605-y","article-title":"Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK\/elF2\u03b1\/ATF4\/CHOP pathway in breast cancer","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/10799893.2019.1655050","article-title":"Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma","volume":"39","author":"Sun","year":"2019","journal-title":"J Recept Signal Transduct Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12032-020-01445-y","article-title":"Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells","volume":"37","author":"Wei","year":"2020","journal-title":"Med Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4\/IKK2\/SNARE-dependent exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"365101","DOI":"10.1088\/1361-6528\/ab94dc","article-title":"Paclitaxel\/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer","volume":"31","author":"Qin","year":"2020","journal-title":"Nanotechnology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12315","article-title":"Induction of immunogenic cell death of esophageal squamous cell carcinoma by 5-fluorouracil and cisplatin","volume":"35","author":"Nishimura","year":"2021","journal-title":"In Vivo"},{"key":"B73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2020.09.011","article-title":"CDK12\/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer","volume":"495","author":"Li","year":"2020","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.015","article-title":"AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells","volume":"15","author":"Lotsberg","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1973197","article-title":"Crizotinib and ceritinib trigger immunogenic cell death via on-target effects","volume":"10","author":"Petrazzuolo","year":"2021","journal-title":"Oncoimmunology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.60135","article-title":"PLK1 inhibition induces immunogenic cell death and enhances immunity against NSCLC","volume":"18","author":"Zhou","year":"2021","journal-title":"Int J Med Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26020511","article-title":"Arginine deiminase induces immunogenic cell death and is enhanced by n-acetylcysteine in murine MC38 colorectal cancer cells and MDA-MB-231 human breast cancer cells In vitro","volume":"26","author":"Huang","year":"2021","journal-title":"Molecules"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02041-8","article-title":"BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade","volume":"40","author":"Tong","year":"2021","journal-title":"Oncogene"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0396","article-title":"A benzenesulfonamide-based mitochondrial uncoupler induces endoplasmic reticulum stress and immunogenic cell death in epithelial ovarian cancer","volume":"20","author":"Bi","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses In vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202013987","article-title":"An ER-targeting Iridium(III) complex that induces immunogenic cell death in non-Small-Cell lung cancer","volume":"60","author":"Wang","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1039\/c9mt00051h","article-title":"First-in-class ruthenium anticancer drug (KP1339\/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro","volume":"11","author":"Wernitznig","year":"2019","journal-title":"Metallomics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1039\/d0mt00227e","article-title":"Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids","volume":"12","author":"Wernitznig","year":"2020","journal-title":"Metallomics"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202000553","article-title":"Immunogenic cell death of breast cancer stem cells induced by an endoplasmic reticulum-targeting Copper(II) complex","volume":"21","author":"Kaur","year":"2020","journal-title":"Chembiochem"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.03.192","article-title":"Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate","volume":"513","author":"You","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01687-8","article-title":"Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis","volume":"40","author":"Fletcher","year":"2021","journal-title":"Oncogene"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13885","article-title":"CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells","volume":"110","author":"Uscanga-Palomeque","year":"2019","journal-title":"Cancer Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2054305","article-title":"PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells","volume":"11","author":"Calvillo-Rodr\u00edguez","year":"2022","journal-title":"Oncoimmunology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152882","article-title":"Oxaliplatin-induced hepatic sinusoidal obstruction syndrome","volume":"460","author":"Zhu","year":"2021","journal-title":"Toxicology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1721810","article-title":"PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models","volume":"9","author":"Yamazaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101430","article-title":"Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours","volume":"49","author":"Karp","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"viii143","DOI":"10.1093\/annonc\/mdy279.424","article-title":"PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors","volume":"29","author":"Karp","year":"2018","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202000131","article-title":"Antitumour anthracyclines: Progress and perspectives","volume":"15","author":"Martins-Teixeira","year":"2020","journal-title":"ChemMedChem"},{"key":"B94","unstructured":"Bethesda (MDNational Institute of Diabetes and Digestive and Kidney DiseasesLiverTox: Clinical and research information on drug-induced liver injury2012"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245986","article-title":"A compressive review about taxol\u00ae: History and future challenges","volume":"25","author":"Gallego-Jara","year":"2020","journal-title":"Molecules"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/biom11091275","article-title":"Emergence of cardiac glycosides as potential drugs: Current and future scope for cancer therapeutics","volume":"11","author":"Kumavath","year":"2021","journal-title":"Biomolecules"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120792","article-title":"Lanatoside c induces G2\/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, wnt, JAK-STAT, and PI3K\/AKT\/mTOR signaling pathways","volume":"9","author":"Reddy","year":"2019","journal-title":"Biomolecules"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25611","article-title":"Anti-tumor effects of cardiac glycosides on human lung cancer cells and lung tumorspheres","volume":"232","author":"Kaushik","year":"2017","journal-title":"J Cell Physiol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1021\/np900210m","article-title":"Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs","volume":"72","author":"Felth","year":"2009","journal-title":"J Nat Prod"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2018.1435540","article-title":"Neuroprotective and tumoricidal activities of cardiac glycosides. could oleandrin be a new weapon against stroke and glioblastoma","volume":"128","author":"Elmaci","year":"2018","journal-title":"Int J Neurosci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0484-z","article-title":"Digitalis use and the risk of breast cancer: A systematic review and meta-analysis","volume":"40","author":"Zhang","year":"2017","journal-title":"Drug Saf"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.755433","article-title":"Immunogenic cell death and immunomodulatory effects of cabozantinib","volume":"11","author":"Scirocchi","year":"2021","journal-title":"Front Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Junwei","year":"2014","journal-title":"Mol Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.45.4.251","article-title":"Targeting arginine-dependent cancers with arginine-degrading enzymes: Opportunities and challenges","volume":"45","author":"Phillips","year":"2013","journal-title":"Cancer Res Treat"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.37","article-title":"Arginine dependence of tumor cells: targeting a chink in cancer\u2019s armor","volume":"35","author":"Patil","year":"2016","journal-title":"Oncogene"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0172-2","article-title":"We need to talk about the warburg effect","volume":"2","author":"DeBerardinis","year":"2020","journal-title":"Nat Metab"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1865","article-title":"Altered mitochondria functionality defines a metastatic cell state in lung cancer and creates an exploitable vulnerability","volume":"81","author":"Chuang","year":"2021","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial metabolism as a target for cancer therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01182","article-title":"Small molecule mitochondrial uncouplers and their therapeutic potential","volume":"61","author":"Childress","year":"2018","journal-title":"J Med Chem"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2020-0003","article-title":"Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer","volume":"15","author":"Ss Pindiprolu","year":"2020","journal-title":"Nanomed (Lond)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0792","article-title":"Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer","volume":"14","author":"Senkowski","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41419-017-0092-6","article-title":"Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer","volume":"9","author":"Alasadi","year":"2018","journal-title":"Cell Death Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101222","article-title":"Exploring the therapeutic potential of mitochondrial uncouplers in cancer","volume":"51","author":"Shrestha","year":"2021","journal-title":"Mol Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-019-0247-4","article-title":"Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells","volume":"14","author":"Zhang","year":"2019","journal-title":"Infect Agent Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111188","article-title":"Therapeutic versatility of resveratrol derivatives","volume":"9","author":"Nawaz","year":"2017","journal-title":"Nutrients"},{"key":"B120","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/187152312803476255","article-title":"Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review","volume":"11","author":"Bacchi","year":"2012","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072605","article-title":"Anti-inflammatory drugs as anticancer agents","volume":"21","author":"Zappavigna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/s0304-3835(01)00476-1","article-title":"Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action","volume":"167","author":"Kozuki","year":"2001","journal-title":"Cancer Lett"},{"key":"B123","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/tcr.201600121","article-title":"Photodynamic therapy: Past, present and future","volume":"17","author":"Chilakamarthi","year":"2017","journal-title":"Chem Rec"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28766","article-title":"High hydrostatic pressure induces immunogenic cell death in human tumor cells","volume":"135","author":"Fucikova","year":"2014","journal-title":"Int J Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13358","article-title":"Cold atmospheric plasma induces HMGB1 expression in cancer cells","volume":"39","author":"Yoon","year":"2019","journal-title":"Anticancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00273","article-title":"Near-infrared photoimmunotherapy of cancer","volume":"52","author":"Kobayashi","year":"2019","journal-title":"Acc Chem Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/s41467-019-11269-8","article-title":"Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664615","article-title":"Graphene-induced hyperthermia (GIHT) combined with radiotherapy fosters immunogenic cell death","volume":"11","author":"Podolska","year":"2021","journal-title":"Front Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1667\/RR13731.1","article-title":"Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells","volume":"182","author":"Aryankalayil","year":"2014","journal-title":"Radiat Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1258505","article-title":"Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death","volume":"6","author":"Moserova","year":"2017","journal-title":"Oncoimmunology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145128","article-title":"Non-thermal plasma application in tumor-bearing mice induces increase of serum HMGB1","volume":"21","author":"Troitskaya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2019.08.017","article-title":"Radiation therapy for prostate cancer","volume":"34","author":"Kamran","year":"2020","journal-title":"Hematol\/Oncol Clin North Am"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09356-y","article-title":"Intraoperative radiation therapy for breast cancer: Are we there yet","volume":"28","author":"Shah","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.06.012","article-title":"Advances in external beam radiation therapy and brachytherapy for cervical cancer","volume":"33","author":"Williamson","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2019.07.153","article-title":"Stereotactic body radiotherapy. how to better protect normal tissues","volume":"23","author":"Pasquier","year":"2019","journal-title":"Cancer Radiother"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2019.09.011","article-title":"Stereotactic body radiotherapy: Passing fad or revolution","volume":"107","author":"Vallard","year":"2020","journal-title":"Bull Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2946","article-title":"A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.01.015","article-title":"High hydrostatic pressure in cancer immunotherapy and biomedicine","volume":"36","author":"Adkins","year":"2018","journal-title":"Biotechnol Adv"},{"key":"B141","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3892\/or.2021.8026","article-title":"Research and application of hydrostatic high pressure in tumor vaccines (Review)","volume":"45","author":"Yan","year":"2021","journal-title":"Oncol Rep"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.07.007","article-title":"Cellular immunotherapy for multiple myeloma","volume":"21","author":"Rosenblatt","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15590-6","article-title":"Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial","volume":"363","author":"Jocham","year":"2004","journal-title":"Lancet"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.968434","article-title":"Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy","volume":"3","author":"Adkins","year":"2015","journal-title":"Oncoimmunology"},{"key":"B145","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.critrevonc.2019.04.023","article-title":"Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies","volume":"139","author":"Lassche","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13304","article-title":"Cold atmospheric plasma, a novel promising anti-cancer treatment modality","volume":"8","author":"Yan","year":"2017","journal-title":"Oncotarget"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051336","article-title":"Intracellular responses triggered by cold atmospheric plasma and plasma-activated media in cancer cells","volume":"26","author":"Motaln","year":"2021","journal-title":"Molecules"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/biology10010041","article-title":"Cold atmospheric plasma, a novel approach against bladder cancer, with higher sensitivity for the high-grade cell line","volume":"10","author":"Tavares-da-Silva","year":"2021","journal-title":"Biol (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031172","article-title":"Photodynamic and cold atmospheric plasma combination therapy using polymeric nanoparticles for the synergistic treatment of cervical cancer","volume":"22","author":"Ha","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06178-3","article-title":"Cold atmospheric plasma induced genotoxicity and cytotoxicity in esophageal cancer cells","volume":"48","author":"Estarabadi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.7150\/jca.54528","article-title":"Cold atmospheric plasma selectively induces G0\/G1 cell cycle arrest and apoptosis in AR-independent prostate cancer cells","volume":"12","author":"Hua","year":"2021","journal-title":"J Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1117","article-title":"Tumor-treating fields: A fourth modality in cancer treatment","volume":"24","author":"Mun","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","first-page":"E3016","DOI":"10.3390\/cancers12103016","article-title":"Tumor treating fields (TTFields) hinder cancer cell motility through regulation of microtubule and acting dynamics","volume":"12","author":"Voloshin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B154","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br J Cancer"},{"key":"B155","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/nyas.12112","article-title":"Tumor treating fields: a new frontier in cancer therapy","volume":"1291","author":"Davies","year":"2013","journal-title":"Ann New York Acad Sci"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103535","article-title":"Tumor-treating fields: A fourth modality in cancer treatment, new practice updates","volume":"168","author":"Arvind","year":"2021","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"v659","DOI":"10.1093\/annonc\/mdz260.116","article-title":"1594TiP - radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial","volume":"30","author":"Mehta","year":"2019","journal-title":"Ann Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2174\/1568009043332727","article-title":"Bacteria and bacterial toxins as therapeutic agents for solid tumors","volume":"4","author":"Michl","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2148","article-title":"Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities","volume":"8","author":"Sedighi","year":"2019","journal-title":"Cancer Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-7555-7_5","article-title":"Oncolytic immunotherapy for treatment of cancer","volume":"909","author":"Tsun","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1952539","article-title":"Alternol triggers immunogenic cell death via reactive oxygen species generation","volume":"10","author":"Li","year":"2021","journal-title":"Oncoimmunology"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba6110","article-title":"Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer","volume":"13","author":"Oresta","year":"2021","journal-title":"Sci Transl Med"},{"key":"B165","article-title":"Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells","volume":"8","author":"Ye","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15089","article-title":"Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells","volume":"24","author":"Wang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0802","article-title":"Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses","volume":"18","author":"Goradel","year":"2022","journal-title":"Future Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12935-022-02585-z","article-title":"Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction","volume":"22","author":"Mardi","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000729","article-title":"History, presence, and future of mitomycin c in glaucoma filtration surgery","volume":"32","author":"Wolters","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-Patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"B175","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s11658-018-0078-0","article-title":"STAT3, stem cells, cancer stem cells and p63","volume":"23","author":"Galoczova","year":"2018","journal-title":"Cell Mol Biol Lett"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2019.52.7.152","article-title":"Highlighted STAT3 as a potential drug target for cancer therapy","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Rep"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.06.006","article-title":"Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma","volume":"48","author":"Adachi","year":"2012","journal-title":"Oral Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00436","article-title":"STAT3 contributes to oncolytic Newcastle disease virus-induced immunogenic cell death in melanoma cells","volume":"9","author":"Shao","year":"2019","journal-title":"Front Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-020-00326-z","article-title":"STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells","volume":"28","author":"Jafari","year":"2020","journal-title":"Daru"},{"key":"B180","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12885-020-06964-5","article-title":"Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells","volume":"20","author":"Solari","year":"2020","journal-title":"BMC Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int J Med Sci"},{"key":"B182","doi-asserted-by":"publisher","first-page":"12264","DOI":"10.1038\/s41598-021-91603-7","article-title":"Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer","volume":"11","author":"Petersen","year":"2021","journal-title":"Sci Rep"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02458-x","article-title":"Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer","volume":"69","author":"Bains","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121027","article-title":"Doxorubicin-near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy","volume":"607","author":"Jin","year":"2021","journal-title":"Int J Pharm"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0228","article-title":"Trifluridine\/Tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages","volume":"7","author":"Limagne","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020535","article-title":"Combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation anti-PD-1 treatment efficacy in urothelial carcinoma","volume":"22","author":"Fukushima","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.02.032","article-title":"Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer","volume":"332","author":"Zheng","year":"2021","journal-title":"J Control Release"},{"key":"B188","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/02656736.2015.1106011","article-title":"Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo","volume":"32","author":"Werthm\u00f6ller","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S285999","article-title":"Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors","volume":"16","author":"Qi","year":"2021","journal-title":"Int J Nanomed"},{"key":"B190","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41419-019-1819-3","article-title":"Extracorporeal photochemotherapy induces bona fide immunogenic cell death","volume":"10","author":"Tatsuno","year":"2019","journal-title":"Cell Death Dis"},{"key":"B191","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1038\/s41598-021-86354-4","article-title":"Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death","volume":"11","author":"Turubanova","year":"2021","journal-title":"Sci Rep"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14425","article-title":"Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity","volume":"8","author":"Ogawa","year":"2017","journal-title":"Oncotarget"},{"key":"B193","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41598-021-81465-4","article-title":"Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer","volume":"11","author":"Katsube","year":"2021","journal-title":"Sci Rep"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31071","article-title":"Nano-pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases","volume":"142","author":"Guo","year":"2018","journal-title":"Int J Cancer"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121180","article-title":"A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase","volume":"279","author":"Guan","year":"2021","journal-title":"Biomaterials"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.04.029","article-title":"Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade","volume":"334","author":"Zhou","year":"2021","journal-title":"J Control Release"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01297-0","article-title":"Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma","volume":"20","author":"Guo","year":"2021","journal-title":"Mol Cancer"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923598","article-title":"Cell membrane-derived vesicle: A novel vehicle for cancer immunotherapy","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1039\/d0tb01052a","article-title":"A cell membrane vehicle co-delivering sorafenib and doxorubicin remodel the tumor microenvironment and enhance immunotherapy by inducing immunogenic cell death in lung cancer cells","volume":"8","author":"Wan","year":"2020","journal-title":"J Mater Chem B"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120546","article-title":"Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment","volume":"268","author":"Zhou","year":"2021","journal-title":"Biomaterials"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.7150\/thno.52570","article-title":"Engineering exosomes for targeted drug delivery","volume":"11","author":"Liang","year":"2021","journal-title":"Theranostics"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b16837","article-title":"Extremely effective chemoradiotherapy by inducing immunogenic cell death and radio-triggered drug release under hypoxia alleviation","volume":"11","author":"Zhu","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029053","article-title":"Photodynamic therapy for stage I and II non-small cell lung cancer: A SEER-Medicare analysis 2000-2016","volume":"101","author":"Chhatre","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000964","article-title":"Current evidence for focal laser ablation and vascular-targeted photodynamic therapy for localized prostate cancer: review of literature published in the last 2 years","volume":"32","author":"Candela","year":"2022","journal-title":"Curr Opin Urol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2022.102860","article-title":"Emerging trends in photodynamic therapy for head and neck cancer: A 10-year bibliometric analysis based on CiteSpace","volume":"38","author":"Zhan","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2021.102671","article-title":"Photodynamic therapy combined with immunotherapy for an advanced esophageal cancer with an obstruction post metal stent implantation: A case report and literature review","volume":"37","author":"Wang","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103325","article-title":"Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications","volume":"161","author":"Paraboschi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2019922","article-title":"CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model","volume":"11","author":"Furusawa","year":"2022","journal-title":"Oncoimmunology"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122996","article-title":"Near-infrared photoimmunotherapy (NIR-PIT) in urologic cancers","volume":"14","author":"Fukushima","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B211","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s10120-019-00988-y","article-title":"Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT","volume":"23","author":"Nishimura","year":"2020","journal-title":"Gastric Cancer"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15013","article-title":"Endoscopic near-infrared photoimmunotherapy in an orthotopic head and neck cancer model","volume":"112","author":"Okada","year":"2021","journal-title":"Cancer Sci"},{"key":"B213","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/intimm\/dxaa037","article-title":"Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity","volume":"33","author":"Kobayashi","year":"2020","journal-title":"Int Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S362759","article-title":"Recent progress of metal-organic framework-based photodynamic therapy for cancer treatment","volume":"17","author":"Ye","year":"2022","journal-title":"Int J Nanomed"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23239","article-title":"Nano-pulse stimulation induces changes in the intracellular organelles in rat liver tumors treated in situ","volume":"52","author":"Nuccitelli","year":"2020","journal-title":"Lasers Surg Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1089\/bioe.2018.0001","article-title":"Application of pulsed electric fields to cancer therapy","volume":"1","author":"Nuccitelli","year":"2019","journal-title":"Bioelectricity"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040097","article-title":"Nanopulse stimulation (NPS) induces tumor ablation and immunity in orthotopic 4T1 mouse breast cancer: A review","volume":"10","author":"Beebe","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1039\/d0nr06587k","article-title":"Laser nanobubbles induce immunogenic cell death in breast cancer","volume":"13","author":"Nguyen","year":"2021","journal-title":"Nanoscale"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106184","article-title":"Advances in intelligent-responsive nanocarriers for cancer therapy","volume":"178","author":"Tian","year":"2022","journal-title":"Pharmacol Res"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.006","article-title":"Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy","volume":"40","author":"Vincent","year":"2022","journal-title":"Cancer Cell"},{"key":"B222","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.copbio.2020.06.007","article-title":"Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy","volume":"66","author":"Yan","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.08.009","article-title":"Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine","volume":"337","author":"Appiah","year":"2021","journal-title":"J Control Release"},{"key":"B224","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.drudis.2020.04.007","article-title":"HPMA-based polymeric conjugates in anticancer therapeutics","volume":"25","author":"Rani","year":"2020","journal-title":"Drug Discovery Today"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s596","article-title":"Drug delivery and nanoparticles:applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int J Nanomed"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S266948","article-title":"Cancer cell-membrane biomimetic boron nitride nanospheres for targeted cancer therapy","volume":"16","author":"Feng","year":"2021","journal-title":"Int J Nanomed"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2020.05.028","article-title":"Hybrid cell membrane-coated nanoparticles: A multifunctional biomimetic platform for cancer diagnosis and therapy","volume":"112","author":"Chen","year":"2020","journal-title":"Acta Biomater"},{"key":"B228","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"B229","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.2174\/1381612827666210830095941","article-title":"Multivesicular liposome: A lipid-based drug delivery system for efficient drug delivery","volume":"27","author":"Gorain","year":"2021","journal-title":"Curr Pharm Des"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235672","article-title":"Recent progress in bioconjugation strategies for liposome-mediated drug delivery","volume":"25","author":"Almeida","year":"2020","journal-title":"Molecules"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b02306","article-title":"Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of IDO pathway","volume":"19","author":"Liu","year":"2019","journal-title":"Nano Lett"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomed (Lond)"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1021\/mp800032f","article-title":"Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution","volume":"5","author":"Dobrovolskaia","year":"2008","journal-title":"Mol Pharm"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b07562","article-title":"Meta-analysis of nanoparticle cytotoxicity via data-mining the literature","volume":"13","author":"Labouta","year":"2019","journal-title":"ACS Nano"},{"key":"B236","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12885-020-07169-6","article-title":"AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer","volume":"20","author":"Antoniotti","year":"2020","journal-title":"BMC Cancer"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669965","article-title":"Autologous dendritic cells in combination with chemotherapy restore responsiveness of T cells in breast cancer patients: A single-arm phase I\/II trial","volume":"12","author":"Bernal-Est\u00e9vez","year":"2021","journal-title":"Front Immunol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.07.003","article-title":"Dendritic cell-based immunotherapy (DCVAC\/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial","volume":"162","author":"Cibula","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","article-title":"Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients","volume":"5","author":"Lin","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T04:59:58Z","timestamp":1668661198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":241,"alternative-id":["10.3389\/fimmu.2022.1017400"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1017400","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"article-number":"1017400"}}